As of April 20, Shenandoah Oncology will reopen our clinic after a temporary closure. During the time of our closure, our facilities were extensively cleaned and sanitized. Additionally, we have completed a comprehensive evaluation and response coordinated with the Virginia Department of Health and have concluded that it is safe to resume treatment in our clinic. The wellbeing of our patients continues to be our top priority. We are instating additional preventive measures to ensure a safe care environment, including:

  • Enhanced screening of anyone entering the facility.
  • Requirement of anyone entering the building to wear a face covering. We will provide procedure masks to patients.
  • The operational flow in our building has been modified to allow maximize spacing between individuals in our facility.

We know how difficult and stressful this time is for patients and their families. Our care team will continue to evaluate the most appropriate way to provide continued treatment for each patient during the pandemic, whether in person at our office or by telemedicine. We’re here for you! Always.

Clinical Trials

Open Trials


At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options.  As a member of US Oncology Research and as a clinical research affiliate of VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.
 

BREAST CANCER – ADJUVANT

NSABP B-53 / S1207

Phase 3 study comparing standard adjuvant endocrine therapy to the combination of standard endocrine therapy plus everolimus in patients with high-risk hormone receptor positive and HER2 negative breast cancer.  Studies show that the addition of everolimus to standard endocrine therapy can delay disease progression in metastatic disease, and the goal of this study is to establish if the combination of everolimus and standard endocrine therapy will increase the cure rate in the adjuvant setting.

NRG-BR003

Phase 3 study of adjuvant therapy comparing doxorubicin and cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative triple negative invasive breast cancer.

NRG-BROO6

Phase 3 randomized study of Pembrolizumab versus observation in patient with triple negative breast cancer who have ≥1cm residual disease or positive lymph nodes after neoadjuvant chemotherapy

 

BREAST CANCER – RECURRENT/ADVANCED

A171601

Phase 2 study assessing the tolerability of Palbociclib with Letrozole or Fulvestrant in patients aged 70 or older with hormone receptor positive and HER-2 negative metastatic breast cancer. Open label, single-arm study.

 

CHRONIC LYMPHOCYTIC LYMPHOMA

USOR 15-005

InformCLL:  A disease registry for patients with chronic lymphocytic leukemia.  The study will track current treatment patterns among CLL patients and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

 

LUNG CANCER, NON SMALL CELL

NONE AT THIS TIME

 

LYMPHOMA

NONE AT THIS TIME

 

MULTIPLE MYELOMA

NONE AT PRESENT

 

OVARIAN

NONE AT PRESENT

 

PROSTATE

NONE AT PRESENT

 

RENAL CELL

NONE AT PRESENT

 

THERAPEUTIC

USOR 18-109

A prospective observational study to estimate the incidence of febrile neutropenia (FN) among subjects with non-myeloid malignancies at high risk for FN and receiving Neulasta onpro kit or other physicians choice for prophylaxis of FN.

 

WEIGHT LOSS

BWEL

Randomized phase 3 study evaluating the role of weight loss in adjuvant treatment of overweight or obese women with early HER-2 negative breast cancer.

Learn More